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Everyone aspires to quality health care. Defining “quality” seems straightforward, yet finding
metrics to measure health care is difficult, a point recognized by Donabedian [1] almost half a
century ago. While we often associate quality with price, Americans have the world’s most
expensive health care system, yet have disappointing patient outcomes [2]. As a means to
improve outcomes and control costs, payers in the United States, United Kingdom, and else-
where are increasingly using metrics to rate providers and health care organizations as well as
to structure payment.
Summary Points
• There is limited evidence that many “quality”measures—including those tied to incen-
tives and those promoted by health insurers and governments—lead to improved
health outcomes.
• Despite the lack of evidence, these measures and comparative “quality ratings” are
used increasingly.
• These measures are often based on easily measured, intermediate endpoints such as
risk-factor control or care processes, not on meaningful, patient-centered outcomes;
their use interferes with individualized approaches to clinical complexity and may lead
to gaming, overtesting, and overtreatment.
• Measures used for financial incentives and public reporting should meet higher
standards.
• We propose a set of core principles for the implementation of quality measures with
greater validity and utility.
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Payers demand data in order to pay providers based on “performance,” but such quality
measures and ratings are confusing to patients, employers, and providers [3,4]. Despite recent
flaws in implementing measures for Accountable Care Organizations (ACOs), the Centers for
Medicare and Medicaid Services (CMS), which administers national health care programs in
the US, is moving towards linking 30% of Medicare reimbursements to the “quality or value”
of providers’ services by the end of 2016 and 50% by the end of 2018 through alternative pay-
ment models [5]; more recently, CMS announced a goal of tying 85% of traditional fee-for-ser-
vice payments to quality or value by 2016 and 90% by 2018 [6]. Earlier this year, the Medicare
Payment Advisory Commission cautioned that “provider-level measurement activities are
accelerating without regard to the costs or benefits of an ever-increasing number of measures”
[7].
Evidence connecting many quality measures with improved health outcomes is modest, and
metrics may be chosen because they are easy to measure rather than because they are evidence-
based [8]. The Institute of Medicine (IOM) has warned against using easily obtained surrogate
endpoints as quality indicators, because achieving them may not yield meaningful health out-
comes [9]. When evidence does exist, the relationship between risk and biomarkers is typically
continuous—yet measures often use discrete cutoffs. With payment at stake, clinicians and
organizations may be tempted to game the system by devoting disproportionate effort to
patients barely on the “wrong” side of a line rather than focusing on those at highest risk
[10,11]. Some well-known quality measures do not perform as intended, or may even be associ-
ated with harm (e.g., drug treatment of mild hypertension in low-risk persons has not been
shown to improve outcomes [the yet-to-be-published SPRINT trial enrolled high-risk partici-
pants]; glycemic control with drugs other than metformin in type 2 diabetes may cause harmful
hypoglycemia yet fail to appreciably reduce morbidity and mortality) (Table 1 and S1 Table)
Table 1. Ways targets distort care (see S1 Table for further detail and references).
Predictable Distortion Example
Prioritizing easier care for healthier
people
Focus on moving a healthy patient’s systolic blood pressure
from 141 mm Hg to 139 mm Hg, thereby crossing the 140 mm
Hg threshold, rather than help someone with a heart attack
history improve from 180 mm Hg to 155 mm Hg.
Overtesting Repeat colon cancer screening too early if prior test not billed for
by current insurer; overuse of colonoscopy [20]. Frequent testing
of low-density lipoprotein (LDL) or Hemoglobin (Hgb) A1c levels
despite no known health beneﬁt.
Distortion of informed consent Test all age-eligible adolescents for chlamydia even if they deny
sexual activity.
Overmedication Use anti-hyperglycemic medications other than metformin to
lower HgbA1c levels in type 2 diabetes, despite limited evidence
of beneﬁt and signiﬁcant risk of harm [21,22].
Distraction from patients’ needs Focus on surrogate markers rather than what is meaningful to
the patient (which is likely not a performance measure).
Flawed sense of actual impact Follow performance measure that is incentivized rather than a
meaningful one, such as smoking cessation, which is not
incentivized.
Privilege process rather than
experience of care
Certify that a rushed well-child visit has happened, not that it
was thoughtful, compassionate, effective, and meaningful.
Expansion of denominator of those who
are considered “sick”
Include patients who marginally meet criteria for diabetes or
hypertension, thus increasing the proportion of patients with
mild, easily controlled disease and assuring that practices have
greater proportions of patients who meet a performance
measure.
doi:10.1371/journal.pmed.1001902.t001
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[12–17]. This phenomenon is described as “virtual quality” [18]. Though some guidelines
emphasize shared decision making [19], patient preferences are rarely addressed in guidelines.
Process and performance metrics are increasingly used as quality measures. One influential
US program has stated that its “incentive payments are determined based on quality measures
drawn from nationally accepted sets of measures” [23]. But these measures are typically derived
from the Healthcare Effectiveness Data and Information Set (HEDIS), whose sponsor states
they “were designed to assess measures for comparison among health care systems, not mea-
sures for quality improvement” (boldface in original) [24]. ACO quality measures not created
by CMS carry the disclaimer that “These performance measures are not clinical guidelines and
do not establish a standard of medical care, and have not been tested for all potential applica-
tions” [25]. When sponsors attach such disclaimers to their metrics, it is appropriate to question
their use in public reporting and financial incentives. Limited understanding of the risks and
benefits of testing, difficulties inherent in the communication of complex risk information, and
misplacement of trust in advocacy organizations make physicians, patients, and payers suscepti-
ble to the erroneous impression that poorly chosen targets are valid and appropriate [26].
In our Massachusetts clinical practices, we have encountered examples of questionable tar-
gets across several organizations, such as the following: encouraging unnecessary urine micro-
albumin testing of diabetic patients already taking angiotensin-converting enzyme inhibitors
or angiotensin receptor blockers [27], unnecessary fecal blood testing in patients who had
undergone colonoscopy within the past 10 years (but not credited because the current insur-
ance plan had not paid for it) [28], instructing women aged 40–49 years to schedule a mammo-
gram rather than engaging them in shared decision making [29], and encouraging clinicians to
start medications immediately for patients with diabetes whose blood pressure, low-density
lipoprotein (LDL), or hemoglobin A1c is mildly elevated, rather than following recommenda-
tions for lifestyle interventions first [30–32]. Similarly, practitioners in the UK have received
incentives for dementia screening, despite criticism that evidence to justify dementia case find-
ing was lacking [33]. If non–evidence-based targets are created and supported with financial
incentives, changes in patient care may be inappropriate (Table 1) [8,34].
Fee-for-service has been a critical driver of runaway costs and disappointing health out-
comes in the US. “Quality”measures provide newer, different incentives, but may not achieve
their purpose and may divert us from more thoughtful approaches and useful interventions,
such as addressing social determinants, multimorbidity, and individualized care [35–39].
We believe there must be fundamental change in our approach to quality measurement.
Surrogate and incompletely validated measures may, at times, appropriately inform quality
improvement, but measures used for public reporting and financial incentives should meet
higher standards. We propose an initial set of principles to guide the development of such qual-
ity measures (Box 1). Such measures should merit public trust, earn the support of clinicians,
and promote the empowerment of patients. Their development should be open and transpar-
ent with careful attention to the best evidence of utility.
Quality improvement is a continuous process. Our principles were developed through con-
sensus and are neither perfect nor exhaustive; like other guidelines, they will benefit from eval-
uation and modification. Good quality measures should inform consumers, providers,
regulators, and others about the quality of care being provided in a setting, so the primary con-
cerns for good measures are content validity and impact on health.
Implications of the Guiding Principles
We are critical of current quality measures and believe many should be abandoned. In a 2013
US Senate hearing, a representative of business interests urged Medicare and other insurers to
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sharply reduce the number of indicators being used and “measure and report the outcomes
that American families and employers care the most about—improvements in quality of life,
functioning, and longevity” [40]. The Institute of Medicine’s 2015 report, Vital Signs: Core Met-
rics for Health and Health Care Progress, highlights how “many measures focus on narrow or
technical aspects of health care processes, rather than on overall health system performance
and health outcomes” and finds that the proliferation of measures “has begun to create serious
problems for public health and for health care” [41,42].
Another recent editorial, highlighting the importance of intrinsic versus extrinsic motiva-
tion for physicians, asks: “How Did Health Care Get This So Wrong?” [43]. In the UK, a study
looking at effects of the Quality and Outcomes Framework (QOF)—a broad-based array of
metrics designed more systematically than similar efforts in the US—concluded that it
appeared to have changed the nature of the consultation so that the biomedical agenda related
to the QOF measures is prioritized and the patient’s agenda is unheard [44].
Patient-centeredness means that quality measures need to reflect outcomes experienced and
valued by patients. Patient satisfaction is clearly a critical construct, but clinicians have a respon-
sibility beyond maximizing satisfaction. Patient-reported outcomes, such as those being gath-
ered by the US National Institutes of Health PROMIS program (www.nihpromis.org) and the
International Consortium for Health Outcomes Measurement (ICHOM) [45], should also be
included. In Table 2, we summarize some of the current, flawed approaches to quality measures
and our recommendations for approaches consistent with our suggested guiding principles.
Our guiding principles (Box 1) first recognize that quality measures should reflect meaning-
ful health outcomes. Surrogate measures do not satisfy this principle. Clinical trial results are
often not attained in the real world, and there should be evidence that quality measures do, in
fact, substantially improve health outcomes across various locales and practice settings. Verifi-
cation will often be beyond the capacity of a single organization. Careful analysis of data from
large populations will be required to ascertain whether the expected benefits are being
produced.
Similarly, extrapolation from observational studies should not be used to determine quality
measures—this often confuses treatment outcomes with natural risk factor distributions.
Box 1. Core Principles for Development and Application of Health
Care Quality Measures
Quality measures must:
1. address clinically meaningful, patient-centered outcomes;
2. be developed transparently and be supported by robust scientific evidence linking
them to improved health outcomes in varied settings;
3. include estimates, expressed in common metrics, of anticipated benefits and harms to
the population to which they are applied;
4. balance the time and resources required to acquire and report data against the antici-
pated benefits of the metric;
5. be assessed and reported at appropriate levels; they should not be applied at the pro-
vider level when numbers are too small or when interventions to improve them
require the action(s) of a system.
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Binary measures based on dichotomizing continuous risk factor measurements (e.g., blood
pressure, hemoglobin A1c) should not be used. Aggregate risk measures, such as the Global
Outcomes Score [10] will usually be preferable to individual risk factors. Quality improvement
efforts based on aggregate measures are more likely to yield true health improvements and
reduce gaming and other distortions in provider activity; aggregate measures are also more
robust than isolated individual risk factors. To maximize use, aggregate measures should be
available for use without charge [46]. One could argue either that, while mathematically com-
plex, these measures should be open source to ensure fairness and transparency or, contrarily,
that to minimize gaming/reverse engineering, they should be black boxes with trusted curators
and frequent updating.
After years of application of “quality”measures tied to incentive payments, many clinicians
have adopted practices to optimize revenue. Some of these practices are now out of step with
current evidence. It is known that frontline clinicians are slow to integrate changes informed
by recent evidence [47]; this problem is compounded when they are paid to do things “the old
way.” It is therefore essential that quality measures evolve in a manner that demonstrates a
timely response to new evidence; in this way, up-to-date quality measures can be a productive
driver of early adoption of evidence-based interventions. The difficulty of changing established
practices also highlights that high-stakes quality measures must be chosen carefully, focusing
on important health outcomes and based on the most robust evidence.
Quality measures should reflect that a provider has elicited, explored, and honored patient
values and preferences, and not merely indicate whether a test or intervention has been per-
formed. To do otherwise strikes at the heart of patient-centered care. Because most health care
interventions carry risk of causing harms, measures should reflect overutilization [16,48] as
well as underutilization of care.
There should be an estimate of the expected magnitude of improved health from each qual-
ity measure. Clinical interventions to decrease smoking have a far greater impact on health
than glycemic control for type 2 diabetes [49–51], yet current approaches obscure these relative
contributions. Similarly, dental care [52] and effective treatment of alcohol [53] and opiate [54]
addiction—highly meaningful to patients and strongly contributory to health (in terms of dis-
ability-adjusted life years)—are currently not quality measures. There should also be recogni-
tion of the potential for unintended downstream consequences, such as causing harm through
Table 2. Comparison of typical performancemeasures and author recommendations.
Current Approaches Recommended Approaches
Binary (cut-point) thresholds of risk Continuous measures of risk
Surrogate outcomes Patient-centered outcomes
No accounting of staff effort required to impact
performance measure
Accounting of staff effort
Lack of emphasis on shared decision-making
and eliciting patient preferences
Individualization and shared decision-making as a
default expectation
No articulation of NNT, NNH, NNS Transparency and referencing of NNT, NNH, NNS
Measures focused on individual risk factors Aggregate risk measures
Isolated morbidities Recognition that multimorbidity may modify or
invalidate some measures in individuals
No accounting for social determinants of health Inclusion of social determinants of health
Multiple metric sources with varying biases and
transparency
Single, independent, transparent, unbiased source
* NNT: number needed to treat; NNH: number needed to harm; NNS: number needed to screen
doi:10.1371/journal.pmed.1001902.t002
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interventions that may lead to overdiagnosis/overtreatment and through the associated oppor-
tunity costs [55].
We call for recognition that there are costs (time and resources) associated with acquiring
and reporting data. The expected benefits of a measure must be weighed against direct and
opportunity costs of data collection. Just as the Paperwork Reduction Act in the US requires an
accounting of the time required for form completion, quality measures should include an esti-
mate of the costs they will require. These costs may be mitigated to the extent that electronic
health records can capture necessary data as part of the care process rather than data entry
being required primarily for measurement.
Finally, there should be acknowledgement that improved health is often the result of actions
by multiple parties at multiple levels, not individual providers. In many cases, patient action
(or inaction) is critical and individual providers have limited influence [56]. Cancer screening
or immunization typically is attributable to the influence of a larger system, not an individual
clinician. It also means that data must be aggregated to a level where the numbers have statisti-
cal meaning, including understanding of signal-to-noise ratios. Also, social determinants of
health are often more influential than individual clinicians. Communities or health care sys-
tems (e.g., ACOs) could be measured on their abilities to influence social determinants of
health, such as food security, housing, etc. Altering these critical social determinants is more
desirable than paternalistic or coercive influence through providers.
Making Progress toward True Quality Measures
No simple strategy exists to move forward quickly, and we must guard against implementing
flawed measures and then, years later, acknowledging their flaws. The best strategy for durabil-
ity is likely one that uses the face validity of health—not surrogate outcomes—as the primary
goal.
What do we know well enough to act upon? Our answers all come with caveats. Global risk
measures are likely to be superior to individual risk factor measurements, but it is difficult to
extrapolate from population findings to the individual. Patient satisfaction is an important,
albeit incomplete, measure of quality. Many measures should be more preference-driven than
we might like to admit, particularly for non-urgent decisions. In addition, asking health care
providers to take responsibility for chronic conditions (e.g., hypertension, diabetes, obesity)
over-emphasizes the role of the clinician. This is especially relevant when public health inter-
ventions that target social and environmental factors are much more likely to influence mean-
ingful outcomes. We propose a set of performance measures that have higher face validity and
better relationship to health (some examples are suggested in Box 2).
Many groups have and will continue to produce metrics they label as “quality measures.”
We propose, however, there should be an impartial curator of quality measures to be used for
financial rewards or public reporting that should be financially and organizationally indepen-
dent of potentially biasing groups. The US Preventive Services Task Force (USPSTF) provides
a model for such an entity.
The American Association of Medical Colleges (AAMC) recently published a set of guiding
principles for public reporting of provider performance [57], but they do not address the
importance of patient-centeredness nor consideration of the potential for gaming. The Choos-
ing Wisely campaign recognizes that quality is diminished when there is overtreatment, but
selection of measures here, too, is problematic. Many quality measures will need to be based
not on receipt of a test or a drug or pushing a risk factor below a target threshold but on facili-
tating an informed decision. Recent IOM recommendations for the development of guidelines
provide a framework for developing quality measures [58].
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We must not continue to mismeasure quality by prioritizing time- and cost-effectiveness
over principles of patient-centeredness, evidence-based interventions, and transparency. Sub-
stantial resources are invested in public quality efforts that suggest progress, but implementing
inappropriate measures is counterproductive, undermines the professionalism of dedicated cli-
nicians, and erodes patient trust. The above principles are offered to help identify what is
important for health, i.e., care that matters, so we may then develop quality measures more
likely to reflect and enhance the quality of care provided, while minimizing opportunities for
distortions such as gaming and avoiding the opportunity costs associated with efforts to opti-
mize surrogate endpoints.
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